Editorials

Eli Lilly's third-quarter 2026 Form 10-Q, filed October 29, shows revenue of $24.40 billion, up 39% from $17.60 billion a year earlier. The top line is still compounding at a rapid clip. The profit lines have not kept pace. Net income rose 16% year over year to $6.45 billion, and diluted EPS has fallen for two straight quarters. The quarterly series below shows where the growth is going and where it is leaking.

Revenue grew 16.0% from the first quarter to the second, adding about $3.2 billion. It then grew 6.2% from the second quarter to the third, adding about $1.4 billion. Against the year-ago quarter, the company added $6.8 billion of revenue in a single year. Compounding at this scale is rare for a company of Lilly's size, and the sequential deceleration is the first thing a long-term holder should track. A business can keep growing and still be slowing in its rate of increase, and the next two quarters will show whether the Q3 step-up was a plateau or a pause.

Net income was $7.40 billion in the first quarter, $7.10 billion in the second, and $6.45 billion in the third. That is two consecutive sequential declines, the second one steeper at 9.1%, while revenue rose in both quarters. Net margin fell from 37.4% to 30.9% to 26.4%. In the year-ago quarter it was 31.7%.

Part of the first-quarter figure is a tax effect. The effective tax rate was 16.4% in the first quarter and about 23% in both the second and third quarters, compared with 22.8% in the third quarter of 2025. Net income in the first quarter was therefore helped by a lower tax charge. The second- and third-quarter run rate reflects the more typical tax burden, and the year-over-year comparison is cleaner: pre-tax income rose 16% from $7.23 billion to $8.41 billion, and net income tracked it.

Gross margin, defined as revenue less cost of goods sold, improved year over year to 83.9% from 82.9%. It was lower than the 85.8% of the second quarter. Cost of goods rose 31% year over year, slightly faster than revenue's 39% would suggest not, but well behind the top line for the quarter overall. The sequential drop from the second quarter, where cost of goods rose 20% against a 6% revenue gain, is the more important signal for the margin trend.

R&D expense rose 22.5% year over year, from $3.47 billion to $4.25 billion. That is well below the 39% revenue growth over the same period, so R&D intensity fell from 19.7% of revenue to 17.4%. On a year-over-year basis, research spending is not outpacing the top line.

The sequential picture is different. R&D rose in each quarter of 2026, from $3.51 billion to $3.82 billion to $4.25 billion. The third-quarter increase of 11.2% was almost twice the 6.2% revenue gain. For a company whose pipeline is its future earnings base, a rising research budget is a deliberate choice. The question for owners is whether the step-up is a durable reset in spending or a single-quarter burst, and whether the programs it funds will earn a return that justifies a permanently higher cost base.

Diluted EPS was $8.26 in the first quarter, $7.94 in the second, and $7.22 in the third. The third quarter was still 16% above the $6.21 reported a year earlier. Share count is not the driver. Diluted weighted shares were about 895.9 million, 893.7 million and 893.4 million across the three quarters, and 898.8 million a year earlier. Share repurchases have been modest in the period, at $377 million in the third quarter according to the cash flow statement. EPS is tracking net income, not a shrinking share base.

Revenue less cost of goods, R&D and SG&A rose from roughly $8.4 billion in the third quarter of 2025 to about $13.1 billion in the third quarter of 2026, a gain of about 56%. Pre-tax income rose only 16%. The difference sits in operating and non-operating lines that the quarterly figures used here do not break out. Acquired in-process R&D is one such line. The FY2025 MD&A put it at $2.9 billion for the full year, and it can move sharply from quarter to quarter. Non-operating items also swung from income of $269 million in the second quarter to expense of $202 million in the third.

For a reader trying to judge earnings quality, that gap is the most important open question in this filing. Revenue growth that converts into operating profit is one thing. Revenue growth that is absorbed by acquired R&D, amortization and financing costs is another, even if it is sound business.

Long-term debt, non-current, stood at $46.99 billion on September 30, 2026, up from $40.87 billion a year earlier. Net property, plant and equipment reached $32.19 billion, up from $22.32 billion. The company is funding capacity build-out partly with borrowed money. Receivables, at $22.09 billion, grew about 37% year over year, close to the pace of revenue, so there is no obvious sign of collection strain in the quarter. The FY2025 MD&A flagged rising pricing pressure from U.S. government pricing agreements, Inflation Reduction Act price setting, tariffs and pharmacy benefit manager negotiations. Those pressures are the ones to watch against the gross-margin trend.

The quarter raises four questions that the next 10-Q should help answer:

• Does revenue growth re-accelerate sequentially, or does the 6% gain in the third quarter mark a lasting slowdown?
• Does gross margin stabilize near the 84% level, or does pricing pressure push it lower?
• Does R&D hold above $4 billion a quarter, and does the spending show up in pipeline milestones?
• Does net margin stop falling, and what happens to the unlisted operating and non-operating lines that account for much of the gap between revenue and pre-tax profit?

The answers will determine whether the 39% revenue growth is turning into the kind of earnings power that a long-term owner is paying for. Until then, the headline is strong growth with compressing margins and a rising cost base.